## **Product Sheet**



Yalelaan 1 3584 CL Utrecht The Netherlands +31 30 253 3421 www.qvquality.com KvK: 30274082 VAT: 8215.17.168 NL88 RABO0153194936

## SARS-CoV-2 spike protein

Q103c MCV-4F6
VHH directed against SARS-CoV-2 spike protein
The disease COVID-19 is caused by the virus SARS-CoV-2 and responsible for the global pandemic starting in 2020. SARS-CoV-2 is a spherical-shaped positive- strand RNA virus. <sup>1</sup> The SARS-CoV-2 spike protein (S protein) is a homotrimeric transmembrane glycoprotein that is one of the major protein complexes on the virus and which plays an important role in infection into host cells. <sup>2</sup> Each spike protein monomer is a 140 kDa protein with an N-terminal S1 domain, a membrane-proximal S2 domain, a transmembrane domain, and a C-terminal domain. <sup>2</sup> Via the receptor binding domain (RBD) within the S1 domain, the spike proteins bind to Angiotensin-Converting Enzyme 2 (ACE2) receptors on host cells, which is then followed by fusion of the virus with the membrane. <sup>2</sup> By interfering with the interaction of the RBD with ACE2, infection can be blocked. <sup>3</sup> Therefore, S1 and RBD in particular, is an interesting therapeutic target for COVID-19. <sup>3</sup>
Recombinant monoclonal VHH (Llama glama), purified from S.cerevisiae using affinity chromatography. Immunization with and phage-display selection on recombinant protein using total elution.
SARS-CoV-2 spike protein domain S1.
0.2 μm filtered solution in PBS.
14.7 kDa 18575 1.3
Shipped on blue ice. Store at 4°C or -20°C (aliquots). Addition of 0.02% sodiumazide is optional.
ELISA, viral neutralisation.
Go gauge for the second

References:

- 1 Sharma et al., (2021) Viruses. 13(2):202
- 2 Khailany et al., (2020) Gene Reports. 100682 3 Walls et al., (2020) Cell. 180:281–292
- 4 Salvatori et al., (2020) J Transl Med 18:222